ANI Pharmaceuticals makes recommended SEK 5.6bn cash offer for Egetis Therapeutics
The board of Egetis unanimously recommends the offer. Shareholders with about 42% of the shares have given irrevocable undertakings, subject to conditions.
US-listed ANI Pharmaceuticals has announced a recommended public cash offer to acquire Stockholm-based Egetis Therapeutics AB at SEK 11.25 per share. ANI values the offer at about SEK 5.6 billion, or about USD 560 million, including outstanding incentive programmes.
The Egetis board unanimously recommends that shareholders and holders of the convertible and warrants accept. Shareholders representing about 42% of outstanding shares have undertaken to accept, subject to conditions including a competing offer threshold.
What ANI is buying
Egetis is a commercial-stage rare-disease company whose lead product, EMCITATE (tiratricol), is the first and only approved treatment for peripheral thyrotoxicosis associated with MCT8 deficiency (Allan-Herndon-Dudley syndrome) in both the European Union and the United States. The European Commission approved it on 12 February 2025 and the FDA on 28 September 2026, according to ANI.
ANI said EMCITATE has potential peak sales of more than USD 300 million in its approved indication, with US and EU orphan exclusivity and patent protection into 2045. The buyer also pointed to an ongoing clinical programme evaluating tiratricol in resistance to thyroid hormone beta (RTH-beta).
Offer terms and conditions
ANI priced the offer at a 27% premium to the 60-day VWAP of Egetis shares. Egetis separately noted premiums of about 12.6% to the 4 November closing price of SEK 9.99, 27% to the 60-day VWAP of SEK 8.86, and 48% to the 180-day VWAP of SEK 7.60. ANI said it will not increase the price unless a competing offer appears.
Completion requires acceptance for more than 90% of outstanding shares on a fully diluted basis and necessary regulatory approvals, including competition and foreign direct investment clearances. The offer is financed with cash on hand and new debt from JPMorgan Chase. The acceptance period is expected around 20 November to 18 December 2026, with settlement around 29 December 2026.
PRV sale and enterprise value
On 4 November 2026, Egetis announced a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher for gross proceeds of USD 190 million. ANI said that, adjusted for estimated PRV net proceeds, the enterprise value reflected in the deal is about USD 434 million.
Advisors and process colour
ANI said Jefferies is its sole financial advisor, with Ropes & Gray and Mannheimer Swartling as legal counsel. Egetis retained Centerview Partners and Advokatfirman Vinge. The Egetis board said the offer followed a competitive process that began after an unsolicited indicative proposal in the third quarter of 2026.
ANI also said it does not intend material changes to Egetis operations, locations, management or employment terms based on current knowledge. Under Swedish takeover rules, the board published that employment view and said it had no reason to question it.
For European biotech boards, the package is a template: cash certainty after dual-region approval, a high acceptance hurdle typical of Swedish squeeze-out mechanics, and a sizeable irrevocable block that makes a successful close more likely if regulators clear the path.
Why it matters for European founders and investors
Swedish rare-disease biotech with an approved EU and US product is scarce. A US acquirer paying a cash premium after FDA approval shows one clear exit path for European specialty pharma that can commercialise first in Europe and then in the US. Compare with other European life-sciences deals in our funding section, including bit.bio's Series D.
Founders should note the structure: a public Swedish offer with a high acceptance threshold, irrevocables at about 42%, and a no-increase statement that still leaves room if a rival bid appears.
What happens next
The acceptance window is expected to open around 20 November 2026. Closing still depends on the 90% threshold and regulatory clearances. If completed, ANI plans to use its rare-disease commercial platform to scale EMCITATE, especially in the United States.
Spotted an error? Email contact@europreneursmedia.com and we'll correct it. See our corrections policy and editorial standards.
